QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis

Muscle Nerve. 2017 Aug;56(2):328-330. doi: 10.1002/mus.25529. Epub 2017 Feb 25.

Abstract

Introduction: A phase 2 study of eculizumab for treating myasthenia gravis (MG) used the quantitative myasthenia gravis score (QMG) and myasthenia gravis activities of daily living profile (MG-ADL) to evaluate baseline disease severity and treatment response. Correlations were then analyzed between these assessments.

Methods: Patients were given eculizumab or placebo during the first 16-week treatment period of the crossover study, with treatment assignments reversed for the second treatment period following a 5-week washout. QMG and MG-ADL scores at baseline and endpoint of each treatment period generated correlation coefficients for baseline status and treatment response during eculizumab therapy.

Results: Correlation strength between QMG and MG-ADL scores was higher for treatment response (R = 0.726; 95% confidence interval, 0.264-0.907; P = 0.0036) than for assessing baseline disease status (R = 0.552; 95% confidence interval, -0.022-0.839; P = 0.0495).

Conclusions: MG-ADL may be more sensitive for assessing treatment response than point-in-time disease status. Muscle Nerve 56: 328-330, 2017.

Keywords: eculizumab; myasthenia gravis; myasthenia gravis activities of daily living profile; patient-reported outcome; physician-reported outcome; quantitative myasthenia gravis.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living / psychology*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cross-Over Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / psychology*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • eculizumab